Tag Archive for: Poolbeg Pharma

Poolbeg Pharma plc – Successful Artificial Intelligence led programme identifies multiple influenza drug targets

/in

AI analysis of unique human challenge trial data provides unparalleled insights into influenza infection Novel influenza drug targets identified faster and more cost-effectively using AI 29 June 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focusing on infectious and other prevalent diseases with a high unmet medical need, announces a significant breakthrough […]

Read more

Poolbeg Pharma Plc – Oral Vaccine Programme Moves Forward

/in

Next Generation Oral Vaccine Programme Advancing Through Non-Dilutive Funding 22 June 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focusing on infectious and other prevalent diseases with high unmet medical needs, announces an update to its Oral Vaccine Programme following the award of non-dilutive grant funding by the Irish Government’s Disruptive Technologies Innovation […]

Read more

Poolbeg Pharma Plc – Board Appointment

/in

24 May 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, announces the appointment of Brendan Buckley as an Independent Non-Executive Director of the Company with immediate effect. Brendan will also replace Cathal Friel as a member of the Remuneration Committee. Read more…

Read more

Poolbeg Pharma Plc: Results for the year ended 31 December 2022

/in

Significant milestones reached, well capitalised and positioned for future growth London, UK 30 March 2023 – Poolbeg Pharma Plc (AIM: POLB, OTCQB: POLBF “Poolbeg” or the “Company”) a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, is pleased to announce its audited results for the year ended 31 December 2022. Read more…

Read more

Poolbeg Pharma plc: POLB 001 patent portfolio strengthened through granting of US patent

/in

Key highlights ·      Patent granted for use of certain p38 MAP kinase inhibitors for the treatment of hypercytokinaemia ·      Allows for use in combination with an antiviral agent ·      Patent enhances the robust IP portfolio protecting Poolbeg’s growing pipeline   8 March 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’),  a leading infectious disease focused biopharmaceutical company, announces that […]

Read more